ClinicalTrials.gg
Not yet recruitingNCT07666243Updated Jun 24, 2026

Outcomes of Embryos Created From Abnormally Fertilized Oocytes

An observational study in Abnormal Fertilization and Infertility, sponsored by Inception Fertility Research Institute, LLC. Not yet recruiting. Open to female participants. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by Inception Fertility Research Institute, LLC · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
92
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-15

Among 10 studies in Infertility by Inception Fertility Research Institute, LLC — 5 open to participants now, 5 under way, none of them phase 3. Infertility · Inception Fertility Research Institute, LLC.

Started
2026
with 2 others
Observational
8 of 10
3 open now
Registered
8th of 10
by date

Among the 10 studies in Infertility by Inception Fertility Research Institute, LLC, this one is one of 3 that started in 2026, is one of 8 observational ones, and was the 8th registered.

Infertility

2,088 studies on the registry are indexed under Infertility; 356 are open to participants now.

Browse Infertility studies →

Open to participants now

5 of the 10 studies in Infertility by Inception Fertility Research Institute, LLC are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 234 Infertility studies recruiting now, 43 (18%) set no upper age limit and 185 (79%) stop at 75 or younger; 27 take children under 18; 76 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Infertility by Inception Fertility Research Institute, LLC, or all of them as a file.
02

Study summary

The purpose of this study is to retrospectively analyze data from multiple clinics in a fertility network on embryos that were created from abnormally fertilized oocytes (AFO) including the rate of transfers and any clinical outcomes in order to inform providers in their decision making regarding AFOs.

03

Conditions studied

  • Abnormal Fertilization
  • Infertility

Browse trials for

Keywords

  • Fertility
  • Reproductive Medicine
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Females of varying age, race, and ethnicity who underwent in vitro fertilization which resulted in a blastocyst derived from an abnormally fertilized embryo

Eligibility criteria

Inclusion Criteria:

  • Underwent in vitro fertilization which resulted in a blastocyst derived from an abnormally fertilized embryo
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
92 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Clinical Outcomes

    For blastocysts derived from AFOs that were transferred, clinical outcomes include implantation rate, ongoing pregnancy rate, live birth rate, and spontaneous abortion rate.

    Time frame: From embryo transfer to delivery

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Hondo S, Arichi A, Muramatsu H, Omura N, Ito K, Komine H, Monzen S, Mukai N, Endo M, Katase S, Kidera N, Sasaki H, Koi H, Yorimitsu T, Ohara M, Kawamura T, Shimizu Y. Clinical outcomes of transfer of frozen and thawed single blastocysts derived from nonpronuclear and monopronuclear zygotes. Reprod Med Biol. 2019 May 15;18(3):278-283. doi: 10.1002/rmb2.12275. eCollection 2019 Jul. PubMed 31312107 ↗
  • Kemper JM, Liu Y, Afnan M, Mol BWJ, Morbeck DE. What happens to abnormally fertilized embryos? A scoping review. Reprod Biomed Online. 2023 May;46(5):802-807. doi: 10.1016/j.rbmo.2023.02.005. Epub 2023 Feb 22. PubMed 36997399 ↗
  • Al Hashimi B, Harvey SC, Harvey KE, Linara-Demakakou E, Raikundalia B, Green O, Griffin DK, Ahuja K, Macklon N. Reassessing the conventional fertilization check: leveraging preimplantation genetic testing for aneuploidy to increase the number of transferrable embryos. Reprod Biomed Online. 2025 Jun;50(6):104595. doi: 10.1016/j.rbmo.2024.104595. Epub 2024 Oct 24. PubMed 40262446 ↗
  • Mutia K, Wiweko B, Iffanolida PA, Febri RR, Muna N, Riayati O, Jasirwan SO, Yuningsih T, Mansyur E, Hestiantoro A. The Frequency of Chromosomal Euploidy Among 3PN Embryos. J Reprod Infertil. 2019 Jul-Sep;20(3):127-131. PubMed 31423415 ↗
  • Girardi L, Patassini C, Miravet Valenciano J, Sato Y, Fagundes Cagnin N, Castellon JA, Cogo F, Zambon P, Blesa D, Jimenez Almazan J, Akinwole A, Coprerski B, Rubio C. Incidence of haploidy and triploidy in trophectoderm biopsies of blastocysts derived from normally and abnormally fertilized oocytes. J Assist Reprod Genet. 2024 Dec;41(12):3357-3370. doi: 10.1007/s10815-024-03278-4. Epub 2024 Oct 8. PubMed 39378000 ↗
  • Ezoe K, Takahashi T, Shimazaki K, Miki T, Tanimura Y, Amagai A, Sawado A, Akaike H, Mogi M, Kaneko S, Kato M, Kato K, Tarozzi N, Borini A, Coticchio G. Human 1PN and 3PN zygotes recapitulate all morphokinetic events of normal fertilization but reveal novel developmental errors. Hum Reprod. 2022 Sep 30;37(10):2307-2319. doi: 10.1093/humrep/deac177. PubMed 35950593 ↗
  • Canon C, Thurman A, Li A, Hernandez-Nieto C, Lee JA, Roth RM, Slifkin R, Briton-Jones C, Stein D, Copperman AB. Assessing the clinical viability of micro 3 pronuclei zygotes. J Assist Reprod Genet. 2023 Jul;40(7):1765-1772. doi: 10.1007/s10815-023-02830-y. Epub 2023 May 25. PubMed 37227570 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2026; primary completion for Jun 2027, 12 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2026
First posted
Jun 24, 2026
StartEst.
Jun 2026
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
Jun 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07666243
Collaborators
Igenomix
Responsible party
Sponsor
First posted
Jun 24, 2026
Start date
Jun 2026 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jun 24, 2026

Study contacts

Laurel Anderson, BS
Contact
landerson@inceptionllc.com
3463621476

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Track this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to track

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion